GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (STU:IQI) » Definitions » Cash-to-Debt

Incannex Healthcare (STU:IQI) Cash-to-Debt : 22.77 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Incannex Healthcare Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Incannex Healthcare's cash to debt ratio for the quarter that ended in Mar. 2024 was 22.77.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Incannex Healthcare could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Incannex Healthcare's Cash-to-Debt or its related term are showing as below:

STU:IQI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2   Med: 5.97   Max: No Debt
Current: 22.75

During the past 13 years, Incannex Healthcare's highest Cash to Debt Ratio was No Debt. The lowest was 0.20. And the median was 5.97.

STU:IQI's Cash-to-Debt is ranked better than
84.34% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs STU:IQI: 22.75

Incannex Healthcare Cash-to-Debt Historical Data

The historical data trend for Incannex Healthcare's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Incannex Healthcare Cash-to-Debt Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.14 1.42 No Debt No Debt No Debt

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 42.38 N/A 30.97 22.77

Competitive Comparison of Incannex Healthcare's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incannex Healthcare's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's Cash-to-Debt falls into.


Incannex Healthcare Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Incannex Healthcare's Cash to Debt Ratio for the fiscal year that ended in Jun. 2022 is calculated as:

Incannex Healthcare had no debt (1).

Incannex Healthcare's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=8.561 / (0.148 + 0.228)
=22.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incannex Healthcare  (STU:IQI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Incannex Healthcare Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Incannex Healthcare (STU:IQI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (STU:IQI) » Definitions » Cash-to-Debt
Comparable Companies
PNXP CYTH BGXX DRRX RMTI QLI CPIX INIS SHWZ TXMD ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
IXHL:USA
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Website
https://www.incannex.com.au
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.